Based on biomedical index data: Risk prediction model for prostate cancer

To explore the influencing factors of prostate cancer occurrence, set up risk prediction model, require reference for the preliminary diagnosis of clinical doctors, this model searched database through the data of prostate cancer patients and prostate hyperplasia patients National Clinical Medical Science Data Center.With the help of Stata SE 12.0 and SPSS 25.0 software, the biases between groups were balanced by propensity score matching. Based on the matched data, the relevant factors were further screened by stepwise logistic regression analysis, the key variable and artificial neural network model are established. The prediction accuracy of the model is evaluated by combining the probability of test set with the area under receiver operating characteristic curve (ROC).After 1:2 PSM, 339 pairs were matched successfully. There are 159 cases in testing groups and 407 cases in training groups. And the regression model was P = 1 / (1 + e (0.122 ∗ age + 0.083 ∗ Apo lipoprotein C3 + 0.371 ∗ total prostate specific antigen (tPSA) −0.227 ∗ Apo lipoprotein C2–6.093 ∗ free calcium (iCa) + 0.428 ∗ Apo lipoprotein E-1.246 ∗ triglyceride-1.919 ∗ HDL cholesterol + 0.083 ∗ creatine kinase isoenzyme [CKMB])). The logistic regression model performed very well (ROC, 0.963; 95% confidence interval, 0.951 to 0.978) and artificial neural network model (ROC, 0.983; 95% confidence interval, 0.964 to 0.997). High degree of Apo lipoprotein E (Apo E) (Odds Ratio, [OR], 1.535) in blood test is a risk factor and high triglyceride (TG) (OR, 0.288) is a protective factor.It takes the biochemical examination of the case as variables to establish a risk prediction model, which can initially reflect the risk of prostate cancer and bring some references for diagnosis and treatment.     

Superb microvascular imaging in guiding targeted biopsy of prostate cancer: A protocol for systematic review and meta analysis

Background:Studies suggested superb microvascular imaging technology to guide prostate cancer biopsy could improve the positive rate of draw materials. The present meta-analysis aimed at determining the accuracy of SMI in the location diagnosis for prostate cancer.Methods:We will search PubMed, Web of Science, Cochrane Library, and Chinese biomedical databases from their inceptions to the October 31st, 2020. Two authors will independently carry out searching literature records, scanning titles and abstracts, full texts, collecting data, and assessing risk of bias. Review Manager 5.2 and Stata14.0 software will be used for data analysis.Results:This systematic review will determine the accuracy of superb microvascular imaging in guiding targeted biopsy of prostate cancer.Conclusion:Its findings will provide helpful evidence for the accuracy of superb microvascular imaging in guiding targeted biopsy of prostate cancer.Systematic review registration:INPLASY2020100117.     

Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency

This study aims to determine the way to predict the haemophilia A (HA) carrier status and the potential severity in six females with low FVIII:C levels (<0.50 IU mL^?1), F8 gene variations and without family history of HA. Except p.Ser577Tyr, F8 gene variations that we reported have never been described (p.Leu107His, p.Pro521Leu, p.Val682Leu, p.Leu2032Pro, p.Ala315dup). Prediction of their potential causal impact was studied by two strategies: bioinformatics approaches and site‐directed mutagenesis followed by FVIII cellular expression into COS‐1 cell. FVIII clotting assay (FVIII:C) and antigen (FVIII:Ag) were assayed in vitro. In silico analysis showed the probably damaging effect of all substitutions and the full conservation of the residues across mammalian species, except for p.Leu2032Pro. The in vitro variant expression model showed abnormal intra and/or extracellular FVIII:C and FVIII:Ag levels for five mutations, which suggest their causality in HA and provide informations about the involved mechanism. We suspect a defect in synthesis and secretion for p.Leu107His, p.Ala315dup and p.Pro521Leu. The mutation p.Val682Leu only affects the FVIII function while p.Ser577Tyr alters function and synthesis. The variant p.Leu2032Pro is probably a polymorphism because no alteration of the FVIII protein expression was observed in vitro. In vitro results suggest that mutations p.Ser577Tyr and p.Ala315dup could led to a severe HA in men. This study demonstrates the ability of this in vitro cellular expression model to contribute to the diagnosis strategy for female suspected of being HA carrier, without HA family history and with a novel F8 gene variation and to provide new criteria for the genetic counselling.     

肝动脉栓塞治疗晚期原发性肝癌破裂大出血的临床应用（附45例分析）

目的探讨肝动脉栓塞（TAE）治疗晚期原发性肝癌破裂大出血临床应用的价值和疗效。方法回顾性分析45例失去手术指征的晚期原发性肝癌破裂大出血患者急诊TAE治疗。其中8例在行TAE治疗的同时行肝动脉化疗栓塞术治疗。结果45例肝癌破裂出血患者全部止血成功,无复发性出血及急性肝功能衰竭发生。结论TAE是治疗晚期原发性肝癌破裂大出血安全、有效和首选的方法。     

Cost effectiveness analysis of population-based serology screening and ^13C-Urea breath test for Helicobacter pylori to prevent gastric cancer： A markov model

AIM：To compare the costs and effectiveness of no screening and no eradication therapy, the populationbased Helicobacter pylori （H pylori） serology screening with eradication therapy and 13C-Urea breath test （UBT） with eradication therapy.
METHODS：A Markov model simulation was carried out in all 237 900 Chinese males with age between 35 and 44 from the perspective of the public healthcare provider in Singapore. The main outcome measures were the costs, number of gastric cancer cases prevented, life years saved, and quality-adjusted life years （QALYs） gained from screening age to death. The uncertainty surrounding the cost-effectiveness ratio was addressed by one-way sensitivity analyses.
RESULTS：Compared to no screening, the incremental cost-effectiveness ratio （ICER） was $16 166 per life year saved or $13 571 per QALY gained for the serology screening, and $38 792 per life year saved and $32 525 per QALY gained for the UBT. The ICER was $477 079 per life year saved or $390 337 per QALY gained for the UBT compared to the serology screening. The costeffectiveness of serology screening over the UBT was robust to most parameters in the model. CONCLUSION：The population-based serologyscreening for H pylori was more cost-effective than the UBT in prevention of gastric cancer in Singapore Chinese males.